Selecta Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update
May 05, 2022 07:30 ET
|
Selecta Biosciences, Inc.
– Phase 1 trial of SEL-302 remains on track to initiate in the second half of 2022 – – DISSOLVE I & II studies on track for completion in Q4 2022 with joint topline readout in Q1 2023 – –...
Selecta Biosciences Announces Six Presentations at the Upcoming 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
May 02, 2022 16:30 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic...
Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Business Update
April 28, 2022 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic...
Selecta Biosciences Announces $38.7 Million Underwritten Offering
April 06, 2022 18:56 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta” or the “Company”), a biotechnology company focused on developing tolerogenic therapies to...
Selecta Biosciences to Participate at the 21st Annual Needham Virtual Healthcare Conference
April 04, 2022 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic...
Selecta Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
March 10, 2022 08:00 ET
|
Selecta Biosciences, Inc.
– U.S. Food and Drug Administration (“FDA”) removed clinical hold on SEL-302 for the treatment of patients with methylmalonic acidemia (“MMA”)- -Observed the synergy of ImmTOR in combination with...
Selecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2021 Financial Results and Provide Business Update
March 03, 2022 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated, precision immune tolerance platform,...
Selecta Biosciences to Participate at the SVB Leerink 11th Annual Global Healthcare Conference
February 09, 2022 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic...
Selecta Biosciences and Ginkgo Bioworks Announce New Collaboration to Develop Next-Generation Gene Therapy Capsids
January 10, 2022 07:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass. and BOSTON, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop...
Selecta Biosciences to Participate at the 2022 H.C. Wainwright BioConnect Conference
January 05, 2022 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic...